首页> 外文期刊>European journal of medical research. >Effect of bone-marrow-derived mesenchymal stem cells on high-potential hepatocellular carcinoma in mouse models: an intervention study
【24h】

Effect of bone-marrow-derived mesenchymal stem cells on high-potential hepatocellular carcinoma in mouse models: an intervention study

机译:骨髓衍生间充质干细胞对小鼠模型高潜能肝细胞癌的影响:干预研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: There are two completely contradictory views regarding the impact of human bone-marrow-derived mesenchymal stem cells (hMSCs) on hepatocellular carcinomas (HCCs). The aim of this study was to investigate the effect of hMSC engraftment on HCC tissues in nude mouse models, and assess the effect on metastatic potential of HCC.Methods: hMSCs were engrafted into the nude mouse models of high metastatic HCC via the tail vein. The mice in the experimental group were engrafted with hMSCs (5 x 10s cells per mouse) via the tail vein 15 days after inoculation of tumor cells, twice a week, while the animals in the control group were injected with hMSC culture medium (0.2 ml_ per mouse) via the tail vein. The subcutaneous tumor size was measured using an electronic digital caliper once every 4 days after hMSC engraftment. After 2, 3,4, 5 and 6 weeks of tumor cell inoculation, the mice were killed and the tumors were collected in their entirety. The tumor weights and body weights of mice were measured, and the tumor inhibition rate was calculated. Quantitative real-time polymerase chain reaction (RT-PCR) was used to determine the expression of metastasis-related genes including osteopontin (OPN), bone sialoprotein (BSP) and integrin ct5 subunit (ct-V) in the mouse models of high-metastatic HCC, and the expression of apoptosis-related genes including B cell lymphoma/leukemia-2 (Bcl2), Bcl-2 associated X protein (Bax) and caspase 3 in tumor samples.Results: The tumor weight inhibition rate was 26.62% at 2 weeks, 52.00% at 3 weeks, 38.20% at 4 weeks, 31.98% at 5 weeks, and 30.23% at 6 weeks. Tumor tissue weight comparison results were significantly lower in the hMSC engraftment groups than in the control group at the second and third weeks. The expression of metastasis-related factors OPN, BSP and ct-V gene was downregulated with time. The expression of antiapoptotic gene Bcl2 exhibited an obvious declining tendency, while the expression of apoptotic genes Bax and caspase 3 showed an obvious rising tendency. The expression of ct-V and BSP significantly correlated positively with the expression of Bcl2, and negatively correlated with the expression of Bax and caspase 3. The tumor inhibition rate was not significantly correlated with the expression of antiapoptotic and apoptotic factors, and ct-V and BSP factors, though it exhibited a significantly negative correlation with the expression of OPN.Conclusions: The highest tumor inhibition rate was observed 3 weeks after hMSCs engraftment, and the tumor inhibition rate gradually reduced with the progression of time. The metastatic potential of tumor cells was downregulated after hMSC engraftment and hMSCs induce further tumor cells apoptosis. The decrease in the proliferation ability of tumor cells may induce a decline in metastatic potential in tumor cells.
机译:背景:关于人骨髓衍生的间充质干细胞(HMSCs)对肝细胞癌(HCCs)的影响有两个完全矛盾的观点。本研究的目的是研究HMSC植入对裸鼠模型中HCC组织的影响,并评估HCC的转移潜力的影响:通过尾静脉将HMSCs植入高转移性HCC的裸鼠模型中。实验组中的小鼠通过在接种肿瘤细胞后15天通过尾静脉(每只小鼠5×10S细胞)(每小时5×10S细胞),每周两次,而对照组中的动物注射HMSC培养基(0.2mL每只鼠标)通过尾静脉。在HMSC植入后每4天使用电子数字卡钳一次测量皮下肿瘤大小。在肿瘤细胞接种的2,4,5和6周后,杀死小鼠并全部收集肿瘤。测量小鼠的肿瘤重量和体重,并计算肿瘤抑制率。定量实时聚合酶链反应(RT-PCR)用于确定在高处小鼠模型中的骨桥蛋白(OPN),骨蛋白(BSP),骨唾液酸蛋白(BSP)和整合素CT5亚基(CT-V)的转移相关基因的表达。转移性HCC,以及肿瘤样品中的B细胞淋巴瘤/白血病-2(BCL2),BCL-2相关X蛋白(BCL2)和Caspase 3的表达相关基因的表达。结果:肿瘤重量抑制率为26.62% 2周,3周,52.00%,4周,33.20%,5周,31.98%,6周,6周内30.23%。 HMSC植入组在第二和第三周的对照组中肿瘤组织重量比较结果显着降低。随时间下调转移相关因子OPN,BSP和CT-V基因的表达。抗凋亡基因Bcl2的表达表现出明显的趋势,而凋亡基因Bax和Caspase 3的表达显示出明显的上升趋势。 CT-V和BSP的表达随着BCl 2的表达而显着相关,并与Bax和Caspase的表达呈负相关。肿瘤抑制率与抗透露凋亡和凋亡因子的表达没有显着相关,CT-V和BSP因子,尽管它与OPN的表达表现出显着的负相关在HMSC植入和HMSCs诱导进一步的肿瘤细胞凋亡之后下调肿瘤细胞的转移潜力。肿瘤细胞增殖能力的降低可能会诱导肿瘤细胞转移潜力的下降。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号